Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...
A late-emerging influenza A mutation known as subclade K weakened protection, but doctors say vaccination still reduces severe illness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback